ondansetron has been researched along with Agoraphobia in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Agoraphobia: Obsessive, persistent, intense fear of open places.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schneier, FR | 1 |
| Garfinkel, R | 1 |
| Kennedy, B | 1 |
| Campeas, R | 1 |
| Fallon, B | 1 |
| Marshall, R | 1 |
| O'Donnell, L | 1 |
| Hogan, T | 1 |
| Liebowitz, MR | 1 |
1 other study available for ondansetron and Agoraphobia
| Article | Year |
|---|---|
Ondansetron in the treatment of panic disorder.
Topics: Administration, Oral; Adult; Agoraphobia; Female; Humans; Male; Middle Aged; Ondansetron; Panic Diso | 1996 |